Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection
暂无分享,去创建一个
S. Paris | M. Cortez | N. Sahoo | Jordan T. Pietz | Yun Hu | H. Barsoumian | F. Masrorpour | S. Gandhi | Q. Nguyen | Qi Wang | C. Leuschner | N. Puebla-Osorio | J. W. Welsh | J. Da silva | Jing Wang | Ethan Y. Hsu | J. Welsh | C. K. Leyton | Shonik Ganjoo | T. Voss | G. Bertolet | Denaha J. Doss | A-H Huang | Qianxia Wang | David P Pollock | Nanez Selene
[1] S. Paris,et al. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer , 2022, Journal of Nanobiotechnology.
[2] S. Paris,et al. Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire , 2022, Cancer Cell International.
[3] F. Ginhoux,et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer , 2022, Cell.
[4] Z. Fridlender,et al. The dual role of neutrophils in cancer. , 2021, Seminars in immunology.
[5] J. Welsh,et al. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model , 2021, Journal of Nanobiotechnology.
[6] D. Nakae,et al. Iron oxide nanoparticles exert inhibitory effects on N-Bis(2-hydroxypropyl)nitrosamine (DHPN)-induced lung tumorigenesis in rats. , 2021, Regulatory toxicology and pharmacology : RTP.
[7] B. Johnston,et al. The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead , 2021, Cancers.
[8] Steven H. Lin,et al. Current Status and Application of Proton Therapy for Esophageal Cancer. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] J. Welsh,et al. Radiotherapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects. , 2021, International journal of radiation oncology, biology, physics.
[10] C. Hedrick,et al. Neutrophils in cancer: heterogeneous and multifaceted , 2021, Nature Reviews Immunology.
[11] Cheng-song Sun,et al. Innate lymphoid cells and cancer: Role in tumor progression and inhibition , 2021, European journal of immunology.
[12] T. Seiwert,et al. A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers. , 2021 .
[13] R. Boidot,et al. Impact of proton therapy on antitumor immune response , 2021, Scientific Reports.
[14] W. Liang,et al. Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma , 2020, Aging.
[15] Raphael Gottardo,et al. Integrated analysis of multimodal single-cell data , 2020, Cell.
[16] A. Mantovani,et al. Neutrophil diversity and plasticity in tumour progression and therapy , 2020, Nature Reviews Cancer.
[17] A. Kwong,et al. Functional Implications of Cathelicidin Antimicrobial Protein in Breast Cancer and Tumor-Associated Macrophage Microenvironment , 2020, Biomolecules.
[18] Feng-Sheng Wang,et al. Epigenetic Regulation of Macrophage Marker Expression Profiles in Kawasaki Disease , 2020, Frontiers in Pediatrics.
[19] M. Minopoli,et al. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy , 2019, Front. Oncol..
[20] M. Gennaro,et al. Foam Cells: One Size Doesn't Fit All. , 2019, Trends in immunology.
[21] B. Ryffel,et al. CD3+ Macrophages Deliver Proinflammatory Cytokines by a CD3- and Transmembrane TNF-Dependent Pathway and Are Increased at the BCG-Infection Site , 2019, Front. Immunol..
[22] S. Paris,et al. DNA damage enhancement by radiotherapy-activated hafnium oxide nanoparticles improves cGAS-STING pathway activation in human colorectal cancer cells. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] R. Weinberg,et al. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade , 2019, Proceedings of the National Academy of Sciences.
[24] S. Formenti,et al. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality , 2019, International journal of radiation biology.
[25] F. Ghiringhelli,et al. Deciphering the Roles of Innate Lymphoid Cells in Cancer , 2019, Front. Immunol..
[26] J. Sicklick,et al. MST1R Kinase Accelerates Pancreatic Cancer Progression Via Effects on both Epithelial Cells and Macrophages , 2019, Oncogene.
[27] K. Tretina,et al. Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease , 2019, The Journal of experimental medicine.
[28] M. Durante. Proton beam therapy in Europe: more centres need more research , 2018, British Journal of Cancer.
[29] D. Guan,et al. Cannabinoid 2 receptor attenuates inflammation during skin wound healing by inhibiting M1 macrophages rather than activating M2 macrophages , 2018, Journal of Inflammation.
[30] F. Hall,et al. Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy , 2018, Molecular therapy oncolytics.
[31] J. Olson,et al. Proton vs. Photon Radiation Therapy for Primary Gliomas: An Analysis of the National Cancer Data Base , 2018, Front. Oncol..
[32] A. Butte,et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.
[33] W. Harmsen,et al. A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer , 2019, Advances in radiation oncology.
[34] Charlotte L. Scott,et al. Macrophages and lipid metabolism , 2018, Cellular immunology.
[35] Yi-xuan Yang,et al. Inhibition of CD9 expression reduces the metastatic capacity of human hepatocellular carcinoma cell line MHCC97-H. , 2018, International journal of oncology.
[36] B. S. Sørensen,et al. "Radiobiology of Proton Therapy": Results of an international expert workshop. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[37] M. Shaul,et al. Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function , 2018, The FEBS journal.
[38] S. Chokshi,et al. Immune checkpoint receptors: homeostatic regulators of immunity , 2018, Hepatology International.
[39] R. Rengan,et al. Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. , 2018, Translational lung cancer research.
[40] Fuqiang Pan,et al. Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma , 2018, Oncology letters.
[41] I. Wistuba,et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.
[42] A. M. Houghton,et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer , 2017, Nature Communications.
[43] Yoshiyuki Hizukuri,et al. Guanylate-binding protein 5 is a marker of interferon-γ-induced classically activated macrophages , 2016, Clinical & translational immunology.
[44] K. Ricketts,et al. Investigation into the effects of high-Z nano materials in proton therapy , 2016, Physics in medicine and biology.
[45] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[46] J. Bae,et al. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment , 2016, Mediators of inflammation.
[47] Irene Garcia,et al. Much More than M1 and M2 Macrophages, There are also CD169+ and TCR+ Macrophages , 2015, Front. Immunol..
[48] M. Okoniewski,et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. , 2015, Immunity.
[49] Liyuan Zhang,et al. Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma. , 2015, International journal of clinical and experimental pathology.
[50] D. Corbeil,et al. Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells , 2015, Oncotarget.
[51] L. Levy,et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. , 2015, Cell reports.
[52] Ben Tran,et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.
[53] C. Garlanda,et al. Tumor associated macrophages and neutrophils in cancer. , 2013, Immunobiology.
[54] C. Garlanda,et al. Tumor associated macrophages and neutrophils in tumor progression , 2013, Journal of cellular physiology.
[55] Kihong Kim,et al. Enhanced proton treatment in mouse tumors through proton irradiated nanoradiator effects on metallic nanoparticles , 2012, Physics in medicine and biology.
[56] R. Palmqvist,et al. The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer , 2012, PloS one.
[57] S. Tsuchida,et al. Malignant Ovarian Tumors with Induced Expression of Carbonyl Reductase Show Spontaneous Regression , 2012, Clinical Medicine Insights. Oncology.
[58] J. Albers,et al. PLTP regulates STAT3 and NFκB in differentiated THP1 cells and human monocyte-derived macrophages. , 2011, Biochimica et biophysica acta.
[59] A. Puig-Kröger,et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. , 2011, Blood.
[60] G. Cheng,et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.
[61] Daxin Wang,et al. Overexpressed PLTP in macrophage may promote cholesterol accumulation by prolonged endoplasmic reticulum stress. , 2017, Medical hypotheses.
[62] D. Hou,et al. Microarray-based determination of anti-inflammatory genes targeted by 6-(methylsulfinyl)hexyl isothiocyanate in macrophages. , 2010, Experimental and therapeutic medicine.